A Phase Ib/II multi-arm, dose finding and expansion study of a novel thymidylate synthase inhibitor with immune modulating properties, NUC-3373, in combination with pembrolizumab or docetaxel in patients with advanced solid tumors (NuTide:303)

Gary Middleton, James Spicer, Burak Aktas, Habana Dinizulu, Richard H Wilson, David J Harrison, Elisabeth Oelmann, Jeff Bloss, Fiona Thistlethwaite
doi: https://doi.org/10.1101/2024.11.07.24316829

Article Information

doi 
https://doi.org/10.1101/2024.11.07.24316829
History 
  • November 8, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Gary Middleton1,*,
  2. James Spicer2,
  3. Burak Aktas2,
  4. Habana Dinizulu3,
  5. Richard H Wilson4,
  6. David J Harrison5,6,
  7. Elisabeth Oelmann6,
  8. Jeff Bloss6 and
  9. Fiona Thistlethwaite3,7
  1. 1Birmingham NHS Foundation Trust/University of Birmingham, UK
  2. 2King’s College London, Guy’s Hospital, London, UK
  3. 3The Christie NHS Foundation Trust
  4. 4Beatson West of Scotland Cancer Centre/University of Glasgow, UK
  5. 5University of St Andrews, UK
  6. 6NuCana plc
  7. 7University of Manchester, UK
  1. ↵*Corresponding author:
    Gary Middleton (g.middleton{at}bham.ac.uk).
Back to top
Posted November 08, 2024.
Download PDF

Supplementary Material

Data/Code
Email
A Phase Ib/II multi-arm, dose finding and expansion study of a novel thymidylate synthase inhibitor with immune modulating properties, NUC-3373, in combination with pembrolizumab or docetaxel in patients with advanced solid tumors (NuTide:303)
Gary Middleton, James Spicer, Burak Aktas, Habana Dinizulu, Richard H Wilson, David J Harrison, Elisabeth Oelmann, Jeff Bloss, Fiona Thistlethwaite
medRxiv 2024.11.07.24316829; doi: https://doi.org/10.1101/2024.11.07.24316829
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area